The efficacy of a second-generation derivative, omaveloxolone (RTA408), has recently been assessed in a preclinical model for diabetic chronic non-healing wounds [277] and, interestingly, omaveloxolone is now being tested in phase-II clinical trial for the Friedreichs ataxia (FRDA), a neurodegenerative condition in which NRF2 activation is suppressed [278, 279]
When starting otherwise well-tolerated therapies causes more inflammation, fatigue, or symptoms, this may reflect toxin mobilization in an already burdened system
This safety feature is particularly important in households with children, as medications should always be kept out of reach
At Medical Weight Loss and Beauty in Pasadena, he offers medically supervised semaglutide treatments backed by clinical expertise and a results-driven approach